CARDENE SR Drug Patent Profile
✉ Email this page to a colleague
When do Cardene Sr patents expire, and what generic alternatives are available?
Cardene Sr is a drug marketed by Chiesi and is included in one NDA.
The generic ingredient in CARDENE SR is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cardene Sr
A generic version of CARDENE SR was approved as nicardipine hydrochloride by ANI PHARMS on October 28th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CARDENE SR?
- What are the global sales for CARDENE SR?
- What is Average Wholesale Price for CARDENE SR?
Summary for CARDENE SR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 173 |
| Clinical Trials: | 9 |
| Patent Applications: | 1,573 |
| DailyMed Link: | CARDENE SR at DailyMed |
Recent Clinical Trials for CARDENE SR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Boston Medical Center | Phase 4 |
| Vanderbilt University Medical Center | Phase 2 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
US Patents and Regulatory Information for CARDENE SR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-001 | Feb 21, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-002 | Feb 21, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-003 | Feb 21, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CARDENE SR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-001 | Feb 21, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-002 | Feb 21, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-003 | Feb 21, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-003 | Feb 21, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-002 | Feb 21, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-001 | Feb 21, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CARDENE SR
See the table below for patents covering CARDENE SR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Italy | 8767057 | ⤷ Sign Up | |
| Japan | S5545075 | ⤷ Sign Up | |
| Norway | 870368 | ⤷ Sign Up | |
| Hungary | 196709 | PROCESS FOR PRODUCING LONG ACTING PHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
| Netherlands | 930023 | ⤷ Sign Up | |
| Germany | 2407115 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
